Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouthwashes for Reducing SARS-CoV-2 Viral Load
NCT04723446Completed
- Sponsor
- Queen Mary University of London
- Start
- May 2021
- Primary completion
- Oct 2021
- Modality
- Conventional Liposomes, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of chlorhexidine, hydrogen peroxide and cetylpyridinium chloride in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Queen Mary University of London. Primary endpoint: Viral load changes in the saliva within groups at 3 hours. Started May 2021; status: completed.
02
Drugs
chlorhexidinehydrogen peroxidecetylpyridinium chloride
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04723446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723446.